Syschem India Ltd. · BSE:SYSCHEM
Syschem India — Investor Presentation (2023)
26 slides from Syschem India's investor presentation, 2023
Slide 1: Investor's Presentation
< Investor's Presentation
Slide 2: Table of Contents
Company Overview Mission & Vision Core Business Table Of Goals & Strategy Key Products Contents Production Volumes Revenue Our Team Our Clients Safe Harbor Statement Thank you
Slide 3: Company Overview
M S$ SYSCHEINDIA Company Overview e Syschem (India) Limited (SIL) is a listed company engaged in the manufacturing of Bulk Drugs/Intermediates and contract manufacturing. It is owned and operated by a highly committed group of techno commercial with extensive experience in the bulkdrug business. Bac
Slide 4: Committed techno-commercial experts in the bulk drug industry
e The Company is committed by its highly committed group of techno-commercial experts with extensive experience in the bulk drug industry. With their expert knowledge and dedicated approach, Syschem India Limited has been able to establish a strong foothold in the industry and offer high- quality pr
Slide 5: Mission & Vision
Mission & The revenue growth comes from three factors - ® ® Vi S O Nn o Largely the capacity expansions o e Increase in distribution network e Adding Product Ranges Back to Agenda Page
Slide 6: SIL's Vision: increase production and reduce import dependency
SIL’s Vision is to increase the production of our existing products and expand our offerings by producing several Intermediates that are currently imported from China for API Industries. Over the next 2-3 years, we aim to reduce our dependency on imports and achieve greater self-sufficiency. To acco
Slide 7: Core Business
Core Business oo : The Company has diversified intermediates products in the Pharmaceuticals which are produced by the chemical route we have a wide range for the formulation Pharmaceuticals Industry. The Company has marked its presence in India and the International market its products have been ex
Slide 8: Core Business: Supply Zone
Core Business Back to Agenda Page Supply Zone We continue to expand our operations and reach to better serve our customers and provide them with the highest level of satisfaction.
Slide 9: Goals & Strategy
Goals & Strategy sack 10 Agendapa Research and The goal of the pharmaceutical Active Pharmaceutical Development (R&D): Ingredient (API) industry is to produce high-quality, safe, The API industry invests heavily in R&D to develop and effective raw materials for the manufacture of drugs new and innov
Slide 10: Sustainability and Supply Chain Management
Back to Agenda Page Sustainability The API industry recognizes the importance of sustainability and is committed to minimizing its environmental footprint through sustainable sourcing practices, reducing waste and emissions, and optimizing energy and water usage. Supply Chain Management: The API ind
Slide 11: Key Products
KEY PRODUCTS Amoxicillin Dicloxacillin Amoxicillin is a widely used Dicloxacillin is an antibiotic antibiotic belonging to the belonging to the penicillin group penicillin group of of antibiotics, specifically antibiotics. classified as a semi-synthetic penicillinase-resistant penicillin Ampicillin
Slide 12: Key Products
Back to Agenda Page KEY PRODUCTS Cephadroxil Cephadroxil is a type of antibiotic that belongs to the cephalosporin family. It works by inhibiting the growth of bacteria and preventing them from reproducing. Cefaclor Cefaclor works by inhibiting the growth of bacteria and preventing them from reprodu
Slide 13: Our aim is to increase production year to year
"Our aim IS to increase Production on year to year basis to achieve our target.” Back to Agenda Page
Slide 14: Production Volume Current Year
PRODUCTION VOLUME CURRENT YEAR QUARTER 1 QUARTER 2 QUARTER 4 Back to Agenda Page
Slide 15: Production Volume by Year
PRODUCTI VOLUME YE FY 21-22 Product Volume for Financial Year 2022 has been 435 Metric Tonnes FY 21-22 435 MT FY 22 - 23 Product Volume for Financial Year 2022 has been 559 Metric Tonnes Back to Agenda Page
Slide 16: Pharmaceutical sales and revenue growth
"Pharmaceutical Sales involve promoting and selling medications to healthcare professionals and institutions to improve patient outcomes and drive Revenue growth for the company.” Back to Agenda Page
Slide 17: Sales & EBITDA Current Year
SALES & EBIDTA CURRENT YEAR Crores QUARTER 1 QUARTER 2 QUARTER 4 EBIDTA ® ® 4 @ 1.4 32.1 32.8 32.6 Crores Crores Crores Crores
Slide 18: Sales & EBITDA FY 21-22 vs FY 22-23
m Series ~ Series 1 2 FY 21-22 SALES -T¥ 66 Cr. 100 EBIDTA - ¥ 69 Lkhs FY 22 - 23 SALES - ¥130.6 Cr. EBIDTA -% 8.89 Cr FY 21- FY 22 - Back to Agenda Page 22 23
Slide 19: Margins & Profit
Sales Report 2023 Margins & 38 @ I’. AYear Increase Rate "Our innovative medications, data-driven strategies, and PA i strong partnerships have driven significant revenue growth for our pharmaceutical company.” MARGINS ( PBT) FY22-%-2.17 Cr. FY 23 -%6.15Cr. FY 22 PROFIT AFTER TAX FY 22 -% -1.71Cr. F
Slide 20: Current Year Growth
CURRENT YEAR GROWTH () Production Growth Sil’s Production has inc. by 29% over the last financial year (22 - 23) 1186% 99% 29% EB Revenue Growth = Sil’'s revenue has inc. by 99% over the ~ last financial year (22 - 23) (3) EBIDTA Growth «8 Sil’s EBIDTA has inc. by 1186 over the last financial year (
Slide 21: Current Year Growth
CURRENT YEAR GROWTH 3647 (2) PBT Growth Sil's Profit Before Tax has inc. by 383% over the last financial year (22 - 23) 383% EB PAT Growth - Sil's Profit After Tax has inc. by 364% over the last financial year (22 - 23) Back to Agenda Page
Slide 22: Our Team
Back to Agenda Page Sales Report 2023 OUR TEAM The backbone of the Indian Pharmaceuticals industry is the bulk drug industry and in the past, a well-developed bulk drugs sector ensured that India "Impressive revenue growth has been a hallmark of our API remained self-dependent on its Producing pharm
Slide 23: Our Clients
OUR LABORATE PHARMACEUTICALS INDIA LTD CLIENTS , . Zimalava SINCE [930 RIVPRA ho | & Velwr] MAXMED LIFE SCIENCES PVT. LTD. Back to Agenda Page
Slide 24: Safe Harbor Statement
SAFE HARBOR STATEMENT This Information Memorandum has been prepared by the Company based on information and data which the Company considers reliable. However, the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, rel
Slide 25: Forward-looking statements
Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known
Slide 26: Thank You
\ THANK YOU A Presentation by - S SYSCHEM Factory at. : Village Bargodam, Tehsil Kalka, Dist. Panchkula, Haryana-133302 Corp Office. : 825, FF, NAC Manimajra, Chandigarh-161001 Email : Info@syschem.in Contact. : 91-9910489212 Back to Agenda Page